These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38286472)

  • 1. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
    Parrondo RD; Dutta N; LaPlant BR; Elliott J; Fernandez A; Zimmerman A; Cicco G; Han B; Heslop K; Chapin D; Sher T; Roy V; Rasheed A; Das S; Chanan-Khan AA; Paulus A; Ailawadhi S
    Br J Haematol; 2024 May; 204(5):1825-1829. PubMed ID: 38286472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
    Kersten MJ; Amaador K; Minnema MC; Vos JMI; Nasserinejad K; Kap M; Kastritis E; Gavriatopoulou M; Kraan W; Chamuleau MED; Deeren D; Tick LW; Doorduijn JK; Offner F; Böhmer LH; Liu RD; Pals ST; Dimopoulos MA
    J Clin Oncol; 2022 Jan; 40(1):40-51. PubMed ID: 34388022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.
    Izutsu K; Kato H; Sekiguchi N; Fujisaki T; Kawakita T; Obara N; Matsue K; Nishimoto M; Hatayama T; Inagaki M; Fujikawa E
    Int J Hematol; 2024 Jul; 120(1):80-90. PubMed ID: 38597986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
    Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
    Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
    Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
    Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
    Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
    Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
    Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
    J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
    Lim KJC; Tam CS
    Expert Opin Pharmacother; 2020 Sep; 21(13):1555-1564. PubMed ID: 32603202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
    Dimopoulos MA; Tedeschi A; Trotman J; García-Sanz R; Macdonald D; Leblond V; Mahe B; Herbaux C; Tam C; Orsucci L; Palomba ML; Matous JV; Shustik C; Kastritis E; Treon SP; Li J; Salman Z; Graef T; Buske C;
    N Engl J Med; 2018 Jun; 378(25):2399-2410. PubMed ID: 29856685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
    Dimopoulos MA; Grosicki S; Jędrzejczak WW; Nahi H; Gruber A; Hansson M; Gupta N; Byrne C; Labotka R; Teng Z; Yang H; Grzasko N; Kumar S
    Eur J Cancer; 2019 Jan; 106():89-98. PubMed ID: 30471652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
    Sekiguchi N; Rai S; Munakata W; Suzuki K; Handa H; Shibayama H; Endo T; Terui Y; Iwaki N; Fukuhara N; Tatetsu H; Iida S; Ishikawa T; Shiibashi R; Izutsu K
    Cancer Sci; 2020 Sep; 111(9):3327-3337. PubMed ID: 32639651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.
    Liu A; Yu H; Hou R; Zhu Z; Zhuang JL; Bao L; Li Z; Liu L; Hua L; Ma Y; Gao D; Jin A; Suo X; Yang W; Bai Y; Fu R; Zheng D; Chen W
    Cancer Med; 2024 May; 13(9):e7177. PubMed ID: 38686615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
    Grunenberg A; Buske C
    Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
    Trotman J; Opat S; Gottlieb D; Simpson D; Marlton P; Cull G; Munoz J; Tedeschi A; Roberts AW; Seymour JF; Atwal SK; Yu Y; Novotny W; Holmgren E; Tan Z; Hilger JD; Huang J; Tam CS
    Blood; 2020 Oct; 136(18):2027-2037. PubMed ID: 32698195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.
    Castillo JJ; Meid K; Gustine JN; Dubeau T; Severns P; Hunter ZR; Yang G; Xu L; Treon SP
    Clin Cancer Res; 2018 Jul; 24(14):3247-3252. PubMed ID: 29661775
    [No Abstract]   [Full Text] [Related]  

  • 19. How to Sequence Therapies in Waldenström Macroglobulinemia.
    Sarosiek S; Treon SP; Castillo JJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
    Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
    Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.